The global postoperative nausea and vomiting (PONV) management market achieved a valuation of USD 1.17 billion in 2023 and is set to witness exponential growth, reaching an impressive USD 3.9 billion by 2033, according to recent industry insights. The market is anticipated to grow at a robust CAGR of 12.8% during the forecast period 2023 to 2033, driven by a combination of increasing surgical volumes and heightened awareness about the importance of effective PONV management for enhancing patient outcomes.
North America and Europe are currently the largest markets for PONV management, primarily due to the high prevalence of PONV in these regions and the availability of advanced healthcare facilities. However, the Asia-Pacific region is expected to experience the highest growth rate in the coming years, due to the increasing number of surgical procedures being performed in countries like China and India, as well as the growing demand for effective PONV management options in the region.
Various companies are working towards developing new and effective drugs for PONV management, including Acacia Pharma, Eisai Co., Ltd., GlaxoSmithKline, Hoffmann-La Roche AG, and Merck & Co., Inc. These companies are also focusing on strategic collaborations and partnerships to expand their market presence and offer better treatment options to patients.
Key Takeaways from the Market Study:
- The global Postoperative nausea and vomiting (PONV) management market is expected to grow with a 12.8% CAGR during 2023 to 2033.
- By distribution channel, hospital pharmacies are expected to hold 49% of the market share in 2023 for Postoperative nausea and vomiting (PONV) management market.
- North America is expected to possess 47% market share for Postoperative nausea and vomiting (PONV) management market in 2023.
- Europe Postoperative nausea and vomiting (PONV) management market size is expected to possess 43% market share in 2023.
“The PONV management market is expected to experience significant growth in the coming years, driven by increasing demand for effective treatment options and advancements in drug development.” states an FMI analyst
Increased Market Attention: Delve into Detailed Trends and Analysis with Our Report!
Competitive Landscape:
Key players in the postoperative nausea and vomiting (PONV) management market are Acacia Pharma, Hoffmann-La Roche AG, Novartis AG, Ani Pharmaceuticals, Inc, Camurus AB, Sanofi S.A., Helsinn Holding S.A., Eisai Corporation, Merck and Co., GlaxoSmithKline Corporation
- Acacia Pharma has developed a patient-controlled analgesia (PCA) system for PONV management. The PCA system delivers a combination of opioids and antiemetic medications through a patient-controlled pump. The system has been shown to be highly effective in reducing the incidence of PONV and improving patient satisfaction.
- Roche’s key antiemetic medications for PONV management is Kytril (granisetron). Kytril is a selective 5-HT3 receptor antagonist that works by blocking the action of serotonin, a neurotransmitter that is involved in the development of nausea and vomiting. The drug is administered intravenously and has been shown to be highly effective in the prevention and treatment of PONV.
Key Segments Profiled in the Postoperative Nausea and Vomiting (PONV) Management Industry Survey
Treatment Type:
- Serotonin Antagonists
- Steroids
- Dopamine Antagonists
- Neurokinin NK-1 Receptor Antagonists
- Non-pharmacological Treatment
Distribution Channel:
- Hospital Pharmacies
- Online Pharmacies
- Retail Pharmacies and Drug Stores
Region:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- Middle East & Africa
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube